

ESPS JOURNAL EDITOR-IN-CHIEF'S REVIEW REPORT

Name of journal: World Journal of Medical Genetics

ESPS manuscript NO: 16286

Title: Adeno-associated virus vectors for human gene therapy

Journal Editor-in-Chief (Associate Editor): Hans van Bokhoven

Country: Netherlands

Editorial Director: Xiu-Xia Song

Date sent for review: 2015-05-07 09:49

Date reviewed: 2015-05-07 17:46

ACADEMIC CONTENT EVALUATION	LANGUAGE QUALITY EVALUATION	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Revision
<input type="checkbox"/> Grade D: Fair		
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Rejection

JOURNAL EDITOR-IN-CHIEF (ASSOCIATE EDITOR) COMMENTS TO AUTHORS

This is an excellent and very useful overview of the use of AAV vectors in gene therapy. Just one comment: In abstract and summary paragraphs AAV-based therapies are mentioned as the first clinically-approved gene therapy (in 2012). This is somewhat confusing as viral-based therapies have been experimented ever since the first gene therapy experiment approved by the US Food and Drug Administration (FDA) occurred in 1990 for ADA-SCID.